Evidence map›Paper›PMID 16709031›Full record

ArticleNeurosurgical focus2006

Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.

Weijun Wang, Chien-Kuo Tai, Allan D Kershaw, Sounkary K Solly, David Klatzmann, Noriyuki Kasahara, Thomas C Chen

Abstract read
In one paragraph

Article in Neurosurgical focus, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.Clinical cancer research : an official journal of the American Association for Cancer Research · 2013
    Article
  11. Article
  12. Current status of gene therapy for brain tumors.Translational research : the journal of laboratory and clinical medicine · 2013
    Article
  13. Article
  14. Retroviral replicating vectors in cancer.Methods in enzymology · 2012
    Article
  15. Review
  16. Article
  17. Adenovirus-retrovirus hybrid vectors achieve highly enhanced tumor transduction and antitumor efficacy in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2011
    Article
  18. Cellular and vaccine therapeutic approaches for gliomas.Journal of translational medicine · 2010
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Weijun WangDepartment of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA.
Chien-Kuo Tai
Allan D Kershaw
Sounkary K Solly
David Klatzmann
Noriyuki Kasahara
Thomas C Chen

Funding

TARGETING OF RETROVIRAL REPLICATION TO TUMORSP01CA059318 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KEDES, LAURENCE H · 1992 to 2005
$8.4M
NCI NIH HHS P01 CA059318NCI NIH HHS P01 CA59318-07
6 · The paper itself

Abstract

objectThe authors had previously reported on a replication-competent retrovirus (RCR) that has been demonstrated to be stable, capable of effective transduction, and able to prolong survival in an intracranial tumor model in nude mice. The purpose of this study was further investigation of this gene therapy option.

methodsThe transduction efficiency of RCR in RG2, an immunocompetent intracranial tumor model, was tested in Fischer 344 rats. The immune response to the RCR vector was expressed by the quantification of CD4, CD8, and CD11/b in tumors. The pharmaceutical efficacy of the suicide gene CD in converting prodrug 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU) was measured using fluorine-19 nuclear magnetic resonance (19F-NMR) spectroscopy. Animal survival data were plotted on Kaplan-Meier survival curves. Finally, the biodistribution of RCR was determined using quantitative real-time polymerase chain reaction (RT-PCR) for the detection of retroviral env gene. There was no evidence of viral transduction in normal brain cells. Neither severe inflammation nor immunoreaction occurred after intracranial injection of RCR-green fluorescent protein compared with phosphate-buffered saline (PBS). The 19F-NMR spectroscopy studies demonstrated that RCR-CD was able to convert 5-FC to 5-FU effectively in vitro. The infection of RG2 brain tumors with RCR-CD and their subsequent treatment with 5-FC significantly prolonged survival compared with that in animals with RG2 transduced tumors treated with PBS. In contrast to the nude mouse model, evidence of virus dissemination to the systemic organs after intracranial injection was not detected using RT-PCR.

conclusionsThe RCR-mediated suicide gene therapy described in this paper effectively transduced malignant gliomas in an immunocompetent in vivo rodent model, prolonging survival, without evidence of severe intracranial inflammation, and without local transduction of normal brain cells or systemic organs.

Indexed as

AnimalsBrain NeoplasmsCell Line, TumorCell SurvivalDisease Models, AnimalDNA, ViralEncephalitisFlucytosineGenes, Transgenic, SuicideGenetic TherapyGenetic VectorsGliomaHumansImmunocompromised HostMaleOncolytic VirotherapyDNA, ViralFlucytosine

Identifiers

PMID16709031
PMCPMC8295718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.